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Abstract
Background: Single-operator, per-oral cholangiopancreatoscopy (SOPCP) enables direct biliopancreatic ductal
visualization, targeted tissue sampling, and therapeutic intervention. At Karolinska University Hospital, SOPCP was
introduced early and has since been extensively utilized according to a standardized protocol. We analysed the
clinical value of SOPCP in the diagnosis and treatment of biliopancreatic diseases in a single high volume center.
Methods: All SOPCP procedures performed between March 2007 and December 2014 were retrospectively reviewed.
Each procedure’s diagnostic yield and therapeutic value was evaluated using a predefined 4 grade scale; 1 - no diagnostic
or therapeutic value, 2 - information gained did not impact clinical decision-making and in case of a therapeutic
intervention, did not alter the clinical course of the patient, 3 - information gained had an impact on clinical
decision-making and in the case of a therapeutic intervention, assisted subsequent disease management, and
finally, 4 - information gained was essential and critical for clinical decision-making and in case of a therapeutic
intervention, solved the clinical problem requiring no further therapeutic actions. Descriptive statistics were used
to analyse results, with uni- and multivariate analyses completed to assess risk of adverse events.
Results: During the study period, 365 SOPCP procedures were performed. We found SOPCP of pivotal importance
(grade 4) in 19% of cases, and of great clinical significance (grade 3) in 44% of cases. SOPCP did not affect clinical
decision-making or alter clinical course (grade 1 and 2) in 37% of cases.
Conclusion: SOPCP offers direct access to the biliopancreatic ducts for both diagnostic and therapeutic purposes, adding
significant clinical value in 64% of cases.
Trial registration: As this is a purely observational and retrospectively registered study in which the assignment of the
medical intervention was not at the discretion of the investigator, it has not been registered in a registry.
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Background
Technological advancement in recent years has led to
per-oral cholangiopancreatoscopy emerging as a solution
to the challenge of diagnosis and treatment in the small
and relatively inaccessible biliopancreatic ductal systems.
As an adjunct to endoscopic retrograde cholangiopan-
creatography (ERCP), it can be performed in one of
three ways [1]; dual-operator or mother-baby cholangio-
scopy, direct per-oral cholangioscopy, or single-operator
(catheter-based) cholangiopancreatoscopy (SOPCP).
There is an international trend towards the use of the
single-operator system, mainly due to ease of use [2]. The
SpyGlass Direct Visualization System (Boston Scientific,
USA) makes use of a standard duodenoscope, enabling a
single operator to insert specially designed optical fibres
via an optical port, with two further available ports, one
for irrigation and the other to function as a working
channel for insertion of the biopsy forceps, lithotripsy
fibres or laser probe [3].
* Correspondence: marcus.reuterwall.hansson@ki.se
1Division of Surgery, CLINTEC, Karolinska Institutet, Center for Digestive
Diseases, Karolinska University Hospital, Huddinge, 114 86 Stockholm,
Sweden
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Reuterwall et al. BMC Gastroenterology           (2019) 19:35 
https://doi.org/10.1186/s12876-019-0953-9
The use of SOPCP has been evaluated both for the
diagnosis of indeterminate bile duct strictures, as well as
for the treatment of ‘difficult’ bile duct stones [4–9]. It
has recently been successfully utilized in patients with
primary sclerosing cholangitis (PSC), enabling targeted
biopsies and navigation of otherwise inaccessible stric-
tures [10]. Additionally, it offers unique options for
visualization, surveillance and early-detection of premalig-
nant lesions in pancreatic ductal epithelium, being par-
ticularly relevant for lesions such as intraductal papillary
mucinous neoplasms (IPMN) [11–16].
Since its introduction, SOPCP has been met with
divergent experiences; on the one hand it is considered
to be a valuable diagnostic and therapeutic tool, with the
other extreme the view that it might represent a dangerous
acquisition of redundant information. Although pro-
cedural success when using SOPCP has been estab-
lished [7, 17], and adverse events described [2], the degree
to which SOPCP specifically alters clinical management
remains to be investigated. At Karolinska University
Hospital, SOPCP has been utilized since 2007, following a
standardized protocol. Accordingly, we have collected a
substantial longitudinal experience. This report critically
analyzes our data, focusing on the clinical utility of
this technology in the diagnosis and treatment of
biliopancreatic disease.
Methods
From 2007 to 2014, all patients undergoing SOPCP with
the SpyGlass Direct Visualization System at the Karolinska
University Hospital, were included for study. Unless the
indication for investigation was complex cholelithiasis, all
patients were discussed at a multidisciplinary team
meeting, where an individualized management plan was
decided on. Complex cholelithiasis was defined as either
‘difficult’ to remove common bile duct stones (stone
removal not achieved by conventional means), or intrahe-
patic stones. Baseline demographics included a physical
status grading according to the American Society of
Anesthesiologists (ASA) classification system where grades
indicate the presence of; I – a normal healthy patient,
II – mild systemic disease, III – severe systemic
disease, and IV – systemic disease a constant threat to life.
Each procedure’s diagnostic yield and therapeutic value
was retrospectively reviewed using a predefined graded
scale as follows; 1 - no diagnostic or therapeutic value, 2 -
information gained did not impact clinical decision-mak-
ing and in case of a therapeutic intervention, did not alter
the clinical course of the patient, 3 - information gained
had an impact on clinical decision-making and in case of
a therapeutic intervention, assisted subsequent disease
management, and finally, 4 - information gained was
essential and critical for clinical decision-making and in
case of a therapeutic intervention, solved the clinical
problem requiring no further diagnostic or therapeutic
actions. The scale was applied to each individual case
by a single independent reviewer, and the final decision
as to the assigned grade was made by determining the
impact the procedure had on the final multidisciplinary
team meeting decision.
All patients routinely received antibiotic prophylaxis
consisting of either intravenous piperacillin+tazobactam
or oral sulfonamid+trimethoprim, administered prior to
the ERCP. According to standard endoscopy suite proto-
col, prophylactic non-steroidal anti-inflammatories were
not administered and in PSC patients brush samples for
cytology and flow cytometry [10] were obtained. De-
tailed criteria for tissue sampling of strictures by
mini-forceps were not defined, and SOPCP-guided biop-
sies were taken at the discretion of the endoscopist
whenever suspicious focal findings were present.
All procedures were carried out under general
anaesthesia with the SpyGlass Direct Visualization System
(Boston Scientific, USA) passed through a standard duo-
denoscope. The first generation Spyglass System consists
of three components; firstly a reusable SpyGlass fibre optic
probe (allowing direct visual guidance and examination of
the respective duct systems), secondly the SpyScope
disposable access and delivery catheter system (capable
of accommodating both optical and accessory devices
used in the biliary system), and finally the disposable
mini-biopsy forceps (used to capture tissue specimens
for histomorphologic diagnosis). The fibre optic probe
has an outer diameter of 0.9 mm, image transmission of
6000 pixels, a 0O direct view, and a field view of 70o.
The light source is a Xenon light connected to the
SpyScope catheter. Electrohydraulic lithotripsy was per-
formed using either a 1.9-Fr coaxial electrode probe
(Olympus Lithotron EL-25, 1000 mJ; Olympus Inc.,
Stockholm, Sweden) or Nortech AUTOLITH®
EHL-generator with 1,9 F bipolar biliary EHL probe
(Northgate Technologies Inc. Elgin, IL, USA).
After successful cannulation of the papilla and posi-
tioning of the guide wire into the ductal system under
investigation, a ductogram was obtained. An endoscopic
sphincterotomy was performed in all patients. In case of
an insufficient previous sphincterotomy, a redo sphinc-
terotomy was performed. The Spyglass system was then
carefully advanced into the relevant duct, with saline
irrigation used for clearance of debris.
In patients with indeterminate strictures, SOPCP was
applied for visually targeted biopsies in cases where
intraductal papillary and nodular structures or irregular
mucosal surfaces could be visualized. The presence of
dilated tortuous or irregular tumor vessels, if present,
was information that could be added to the clinical data
in each case, and was taken into account at subsequent
multidisciplinary discussion. For the endoscopic diagnosis
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of IPMN, previously defined criteria were used [13, 15].
When discrete, circumscribed areas containing finger like
protrusions, mucus or tumour vessels were identified,
biopsy specimens were obtained from several different
parts of the lesion under direct vision. In the absence of
discrete lesions, random samples from the ductal epithe-
lium were taken and sent for examination by a pathologist.
In many of these patients brush cytology specimens were
also obtained.
Intra- and postprocedural adverse events were graded
according to the American Society for Gastrointestinal
Endoscopy (ASGE) severity grading system [18].
Descriptive statistics were used such as frequencies, me-
dian values, and ranges. Uni- and multivariate analyses
were done to address risk factors for the occurrence of
postprocedural adverse events. All analyses were carried
out using STATA 13.1 (StataCorp LP, College Station,
Texas, USA).
The study protocol was approved by the regional research
ethics committee at Karolinska Institutet, Stockholm,
Sweden (dn 2014/55–31/4).
Results
During the 7-year period, 365 Spyglass procedures were
completed in 311 patients. Demographic details of pa-
tients undergoing SOPCP are represented in Table 1.
The majority of patients had only one procedure. The
median duration of SOPCP was 99 min (range 50–275
min), including procedures such as ERCP and endo-
scopic ultrasound (EUS) performed during the same
anaesthetic. This suggests a certain degree of complexity
and time needed for completion.
Specific indications for patients undergoing SOPCP
are shown in Table 2. The main indication was inde-
terminate bile duct strictures in non-PSC patients. Com-
plex cholelithiasis, was an indication for the procedure
in only 16% of the cases. In 71% of our patients, the bile
duct was the main target, the pancreatic duct in 24%,
and both ducts in 5%.
In 291 (79.6%) patients the procedure could be per-
formed in an outpatient setting. Intra- and post
procedural adverse events are presented in Table 3. We
found an overall adverse event rate (AER) of 16%, with the
majority of these being scored as mild or moderate.
The most frequent adverse event was pancreatitis in 8%
of cases, with an equal distribution between mild and
moderate pancreatitis. We were unable to demonstrate a
change over time regarding the risk for this complication.
Cholangitis was recorded in 16 patients (4%), of which no
cases were severe. We experienced one fatal adverse event
which was due to severe pancreatitis. In this patient an
endoscopic ultrasound-guided puncture of a cystic
pancreatic lesion had been performed in combination with
the SOPCP. Initially a gastro-intestinal perforation was
suspected, but this could not be verified on imaging. The
clinical course was complex, ending in multi-organ failure
and death on day 101. The subsequent autopsy revealed
severe necrotizing pancreatitis.
When analysing specific risk factors for the occurrence
of postprocedural adverse events, we found that pan-
creatoscopy was associated with an AER of 19.8% as
compared to 9.6% for cholangioscopy. In the pancreato-
scopy group we furthermore found a non-dilated main
pancreatic duct in 9 of the 17 pancreatitis cases (53%).
When the clinical value of the respective SOPCP pro-
cedures were carefully scrutinised, a significant gain
(grade 3–4) was detected in 64% of the cases (Fig. 1).
The largest number of grade 2 procedures were due to
an inability to definitively ascertain the relative contribu-
tion of the information provided by the SOPCP, in the
presence of multiple factors that ultimately affected the
clinical decision making process (n = 54).
Table 4 is a representation of the assigned grades
(grouped as grade 1–2, or grade 3–4) according to the
individual indications for SOPCP. In 79% of procedures
performed for the treatment of complex bile duct stones,
therapeutic value was graded as 3–4, whereas in 66% of
procedures performed as part of work-up for cystic
Table 1 Patient demographics for single-operator, per-oral
cholangiopancreatoscopy (SOPCP)
Total SOPCP procedures 365
Number of patients 311
Patients undergoing a single procedure 273 (88%)
Patients undergoing multiple procedures 38 (12%)
Female gender 137 (44%)
Age 64 (4–94)
Referrals from outside Stockholm 103 (33%)
Duration of procedures in minutes 99 (50–275)
ASA 1 58 (16%)
ASA 2 186 (51%)
ASA 3 121 (33%)
ASA 4 0 (0%)
Figures are based on numbers of SOPCP procedures as n (%) or median
(minimum-maximum). ASA American Society of Anesthesiologists
Table 2 Indications for single-operator, per-oral
cholangiopancreatoscopy (SOPCP)
Complex cholelithiasis 58 (15.9%)
Indeterminate strictures (non-PSC patients): 119 (32.6%)
Indeterminate strictures (PSC patients) 82 (22.5%)
Cystic lesions of the pancreas (including IPMN) 64 (17.5%)
Chronic pancreatitis ± lithotripsy 20 (5.5%)
Miscellaneous 22 (6%)
Figures are based on numbers of SOPCP procedures as n (%)
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pancreatic lesions, diagnostic yield was graded as 3–4.
For the evaluation of indeterminate biliary strictures,
both in non-PSC and PSC patients, the diagnostic yield
was graded as 3–4 in 57 and 56% of cases respect-
ively. The clinical value of SOPCP in patients with
chronic pancreatitis was graded as 1–2 in 55% of
patients.
Discussion
Our study represents the largest single institution ex-
perience in the use of the SOPCP (SpyGlass) technique
in routine clinical practice. Our results suggest it offers
important options for direct intraluminal visual inspec-
tion, with the added possibility of targeted biopsies and
therapeutic intervention in both the biliary (71%), and
the pancreatic (23%) ductal systems. SOPCP significantly
impacted or solved the clinical problem in 64% of the
cases. The currently used grading system for diagnostic
and therapeutic yield of SOPCP carries a risk of bias
towards grade 3–4 scoring, and this issue will have to be
addressed in a future validation study to establish inter-
observer reliability. A significant caveat accompanying
the use of SOPCP, is the 16% risk of adverse events.
The Spyglass System was first devised and clinically
tested in 2005–2006 by Chen and Pleskow [17]. Since
then, various groups have reported their initial expe-
rience, although numbers are often small, data collection
retrospective and outcome measures varied. Procedural
success has consistently been reported by most inves-
tigators to be above 90% [19–26].
The most frequent indication for SOPCP in our
patient population was the characterisation of indeter-
minate biliary strictures, one of the most challenging
tasks clinicians are often faced with. Conventional
methods of investigation such as cross-sectional imaging,
as well as emerging modalities such as endoscopic
ultrasonography and intraductal ultrasonography, are
plagued with diagnostic uncertainty. Attempts at tissue
sampling during ERCP with either brush cytology and/or
ERCP-directed biopsy, have not yielded consistent results
[27–31]. Two recent meta-analyses defined the sensitivity
and specificity of SOPCP to diagnose indeterminate
strictures [4, 32]. Both revealed a high sensitivity of
visual impression (84.5–90%) for evaluating strictures
as malignant, with a high specificity for SpyBite biopsy
(98%) as confirmation. One of the limitations with analyses
attempting to define diagnostic capability, is the possible
lack of a ‘gold standard’ for verification of the diagnosis.
Accordingly, with benign strictures of the bile duct,
such as PSC, corroborating histology is usually un-
available. In 56–57% of our patients undergoing
SOPCP for the evaluation of indeterminate bile duct
strictures, the attributed clinical value was graded as
high (grade 3–4). Our results are consistent with previ-
ously published data indicating the persistent diagnos-
tic challenge regarding indeterminate strictures, but
the final assessment of the diagnostic precision of the
system, has to be further elucidated within the frame
of large prospective series with adequate standards for
comparison.
Table 3 Adverse events after SOPCP
N (%)




-fatal outcome 1 (0.3)












Adverse events classified according to the ASGE guidelines [18]
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An important therapeutic indication for cholangioscopy
is the treatment of ‘difficult’ bile duct stones, where duct
clearance cannot be achieved by conventional means. A
recent meta-analysis on the overall performance of all
types of peroral cholangioscopy reported a stone clearance
rate of 88% for bile duct stones [33]. Both electrohydraulic
and holmium laser lithotripsy can be delivered via the
SpyGlass system, and in our study complex cholelithiasis
was the indication in 16% of cases. Although this is a small
percentage of the total SOPCP cohort in out experience,
in 79% of these procedures the therapeutic value of
SOPCP was graded as high (grade 3–4). While our results
draw attention to the established role of cholangioscopy in
the treatment of complex biliary stone disease, it also
suggests least therapeutic benefit for stones associated
with chronic pancreatitis.
In our experience the most common indication for pan-
creatoscopy was a cystic lesion of the pancreas, including
IPMN, and in 66% of these procedures, diagnostic yield
was high (grade 3–4). The malignant potential of
cystic lesions of the pancreas is notoriously difficult to
accurately determine from conventional investigation
methods, leading to complex decision making when
choosing a treatment strategy [34, 35]. In patients with
established or suspected IPMN we observed that at
the time of pancreatoscopy, intraductal accumulation
of mucous was a consistent finding.
There are certain technical limitations that warrant
discussion. This study evaluates the first generation of
the Spyglass system, where image quality has been one
of the major drawbacks. The development of high-defin-
ition video technology will certainly enhance image qual-
ity [36]. Considering the current constraints,
visualization can be optimized by free irrigation of saline,
and adequate suctioning and drainage via a generous
sphincterotomy.
Pancreatitis was the most frequent adverse event after
SOPCP in our study, and like others [2, 20, 23, 37], we
acknowledge this risk. It is not surprising that introduc-
tion of the device into, and manipulation inside of the
main pancreatic duct emerged as a significant risk factor
for post procedural pancreatitis. In our experience, irri-
gation with saline is necessary to clear the endoscopic
view, and gentle handling and careful advancement of
the device through the central parts of the main duct is
mandatory to avoid damage. Although not allowing for
further statistical analysis, a significant number of cases
that developed pancreatitis had a main pancreatic duct
Table 4 Representation of assigned grades
Indication Total n Grades 1–2 n (%) Grades 3–4 n (%)
Complex cholelithiasis 58 12 (20.7) 46 (79.3)
Indeterminate strictures (non-PSC patients): 119 51 (42.9) 68 (57.1)
Indeterminate strictures (PSC patients) 82 36 (43.9) 46 (56.1)
Cystic lesions of the pancreas (incl. IPMN) 64 22 (34.4) 42 (65.6)
Chronic pancreatitis ± lithotripsy 20 11 (55.0) 9 (45.0)
Miscellaneous 22 7 (31.8) 15 (68.2)
Fig. 1 The relative (%) distribution of diagnostic yield and therapeutic value as scored according to the predefined 4 grade scale
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with a normal diameter. Whether other procedure
related factors play a role in the risk for pancreatitis is
still unknown. One lethal adverse event is serious
enough to highlight the need for careful dissemination
of this technology outside of dedicated, specialized
centers. Future studies will further our understanding of
how adverse event risk can be minimized.
Our study was not a prospectively controlled analysis,
but rather observational in design, assessing data from
consecutive patients undergoing SOPCP. This can intro-
duce bias toward visual impression, if the clinical history
and results of prior investigations are known to the
endoscopist. However, because we are scrutinising a new
and evolving technical procedure, we believe that the
endoscopist should have as much clinical information
available as possible to maximize diagnostic and thera-
peutic yield at the time of the investigation.
Conclusion
SOPCP offers unique information from intraluminal
visual inspection and therapeutic intervention of the
biliary (71%) and pancreatic ducts (23%), but is burdened
by a 16% risk of adverse events. We found the procedure
to have significant clinical value in 64% of cases, firmly
establishing its role as an important diagnostic and thera-
peutic adjunct to ERCP, and mandating further careful
and critical exploration.
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